Sign Up Today and Learn More About LISCure Biosciences Stock
Invest in or calculate the value of your shares in LISCure Biosciences or other pre-IPO companies through EquityZen's platform.
LISCure Biosciences Stock (LIBI)
LISCure Biosciences is a biotech company that researches and develops bacteria-mediated immunotherapy.
About LISCure Biosciences Stock
Founded
2018
Industries
Software, Artificial Intelligence, Data and Analytics
LISCure Biosciences Press Mentions
Stay in the know about the latest news on LISCure Biosciences
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
prnewswire • Mar 20, 2025
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
en • Mar 20, 2025
Pharmaceutical composition for preventing or treating intestinal damage …
patents • Apr 15, 2024
Composition for treating brain disease comprising pediococcus inopinatus or …
patents • Apr 15, 2024
Pharmaceutical composition for preventing or treating cancer, comprising …
patents • Apr 15, 2024
LISCure Biosciences Management
Leadership team at LISCure Biosciences
Co-Founder & Chief Executive Officer
Hwaseop Chin
CFO
Junyoung Kil
Join now and verify your accreditation status to gain access to:
- LISCure Biosciences Current Valuation
- LISCure Biosciences Stock Price
- LISCure Biosciences Management
- Available deals in LISCure Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- LISCure Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- LISCure Biosciences Revenue and Financials
- LISCure Biosciences Highlights
- LISCure Biosciences Business Model
- LISCure Biosciences Risk Factors
- LISCure Biosciences Research Report from SACRA Research
Trading LISCure Biosciences Stock
How to invest in LISCure Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like LISCure Biosciences through EquityZen funds. These investments are made available by existing LISCure Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell LISCure Biosciences stock?
Shareholders can sell their LISCure Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
